Could less steroid be just as good for kids with kidney disease?
NCT ID NCT06635720
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a lower dose of the steroid prednisone can treat relapses of nephrotic syndrome in children as effectively as the standard dose. Fifty children aged 1 to 18 with active relapses will be randomly assigned to either the reduced-dose or standard-dose regimen. The goal is to see if this approach is feasible and safe, potentially leading to fewer steroid side effects in the future.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Prednisone (steroid)
- What this could lead to
- If successful, this could lead to a safer, lower-dose steroid regimen for children with nephrotic syndrome, reducing side effects while maintaining disease control.
- What could go wrong
- This is a small pilot study (50 children) at one hospital, so results may not apply broadly. The lower dose might be less effective at controlling relapses.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEPHROTIC SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The Hospital for Sick Children
Toronto, Ontario, M5G 1E8, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- One infusion may keep childhood kidney disease at bay — a trial puts it to the test
- Can a single Immune-Targeting drug quiet an autoimmune kidney disease?
- Scientists probe kidney cell metabolism to unlock secrets of ANCA vasculitis
- Kidney disease biobank aims to unlock new treatments
- Scientists hunt for genes behind kidney disease
- Can a phone app slow kidney disease? new trial aims to find out